Methotrexat Phares (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed for folate metabolism. This inhibition disrupts the synthesis of nucleotides required for DNA replication, leading to decreased proliferation of rapidly dividing cells such as immune cells and cancer cells. The result is reduced inflammation in autoimmune diseases and slowed tumor growth in malignancies.

The specific dose of Methotrexat Phares is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and other individual factors. Healthcare providers calculate the appropriate amount and schedule, and patients should follow the prescriber’s instructions exactly.

Methotrexate is classified as pregnancy category X because it is known to cause fetal harm and birth defects. It is contraindicated in pregnancy and should be stopped well before conception. Breastfeeding is also not recommended, as the drug can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate is one of the most widely used antimetabolites, offering a broad therapeutic range from autoimmune diseases to several cancers. Compared with newer agents like pemetrexed or pralatrexate, methotrexate is generally less expensive and has a longer safety record, though individual response and toxicity profiles may differ, requiring clinician judgment.

Methotrexat Phares should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Do not store at room temperature for extended periods, as stability may be compromised.

The product is supplied as an injectable solution for intramuscular, intrathecal or intravenous administration. The route, dose volume and infusion rate are selected by the treating physician based on the indication and patient characteristics. Administration should be performed by qualified healthcare personnel in an appropriate clinical setting.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound myelosuppression leading to infection or bleeding, renal failure, and rare neurotoxicity when given intrathecally. Patients should be monitored regularly for liver enzymes, blood counts and renal function, and any signs of infection or respiratory distress should prompt immediate medical evaluation.

Methotrexat Phares is contraindicated in pregnant or breastfeeding individuals, patients with severe hepatic impairment, uncontrolled infections, and those with known hypersensitivity to methotrexate or any excipients. Caution is also advised for patients with pre‑existing lung disease, renal insufficiency, or significant bone marrow suppression.